A Chinese biotech partners with GSK to boost its coronavirus vaccine development
A Chinese biotech has taken up vaccine maker GSK’s offer to share its vaccine-boosting platform as it works to develop a product that can stop infection from the novel coronavirus, the companies announced Monday.
The company, Clover Biopharmaceuticals, started working on its vaccine last month, as the outbreak of the virus in China grew. Under the partnership, GSK will provide Clover with its proprietary adjuvants — compounds that enhance the effectiveness of vaccines.
